Advertisement
Home Tags Diabetes: Drugs

Tag: Diabetes: Drugs

More Americans Will Only Have to Pay $35 a Month for Insulin in 2024

By Robin Foster HealthDay Reporter TUESDAY, Jan. 2, 2024 (HealthDay News) -- Managing diabetes will be a less expensive proposition for more Americans in 2024.Sanofi has...

Metformin Does Not Improve Survival in High-Risk Breast Cancer

Incidence rate of invasive disease-free survival events and incidence rates for death did not differ with addition of metformin, placebo

Skyrizi Approved for Psoriatic Arthritis

Mounjaro Approved for Blood Glucose Control in Type 2 Diabetes

The once-weekly injection is approved as an addition to diet and exercise

Medication Type for T2DM May Affect Severe COVID-19 Outcomes

Premorbid GLP1-RA use, SGLT2i use associated with lower 60-day mortality compared to premorbid DPP4i use

Study Looks at T2DM, Metformin Use, and Breast Cancer Risk

Links between T2DM with metformin use and breast cancer risk appear to be affected by hormone receptor status

Infected patient in quarantine lying in bed in hospital

Metformin Use May Reduce Mortality in Women With COVID-19

In overall sample of men and women, metformin use was not linked to significantly reduced mortality

Use of aspirin

Use of Common Meds Tied to Lower Lung Cancer Mortality

Combined use of aspirin, statins, metformin tied to lower lung cancer risk and mortality
A recall of the widely used diabetes drug metformin was announced by drug maker Apotex due to possible high levels of N-Nitrosodimethylamine

Metformin Recalled Due to Potential Cancer-Causing Chemical

Recall is for all lots of metformin hydrochloride extended-release tablets 500 mg from Apotex
Insulin and other biologic drugs

FDA: Insulin Among Drugs Transitioned to Biological Products

New regulatory pathway for biologic drugs allows for approval of biosimilars, interchangeable versions
Initiation of therapy with sodium-glucose cotransporter-2 inhibitors for type 2 diabetes mellitus is not associated with an increased risk for urinary tract infection events compared with initiation of other second-line antidiabetic medications

SGLT-2 Inhibitor Use Not Linked to Increased Risk for UTI Events

Findings seen in propensity-matched cohorts versus receipt of DPP-4 inhibitors or GLP-1 agonists